Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 490 results for "fda centre for drug evaluation and re..."

Roche to initiate testing for Zika virus at U.S. Blood Centres...

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has provided approval to initiate collection and testing of blood samples for screening with the cobas ® Zika assay under an ... Barchart, 1 month ago
[x]  

Roche's investigational medicine ocrelizumab gets US FDA breakthrough therapy status to treat patients with PPMS

Roche announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational medicine ocrelizumab (OCREVUS) for the treatment of people with primary progressive multiple sclerosis (PPMS). There ...
 PharmaBiz2 months ago Roche (RHHBY)'s Multiple Sclerosis Drug Awarded Breakthrough Status from the FDA 2/17/2016  ClinicSpace2 months ago Roche Bearer Share : U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis  4 Traders2 months ago U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis  Pharmacy Choice2 months ago
[x]  
European Pharmaceutical Review

FDA approves Lilly's Taltz for plaque psoriasis

The US Food and Drug Administration (FDA) has approved Lilly's Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients. Taltz's active ingredient is an antibody (ixekizumab) that binds to a protein (interleukin ...
 European Pharmaceutical Review1 month ago

Reports from University of Zurich Provide New Insights into Osteoporosis (Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey)

By a News Reporter-Staff News Editor at Diabetes Week Data detailed on Metabolic Bone Diseases have been presented. According to news reporting from Zurich, Switzerland, by NewsRx journalists, research stated, "To evaluate, across a spectrum of ...
 Pharmacy Choice1 month ago
EuroInvestor

Positive Results From Summit&aposs Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection

(GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (???CDI???), announces the presentation today of ...
 Tutorial Finder2 weeks ago Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection  Benzinga.com2 weeks ago SUMMIT THERAPEUTICS : Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection  4 Traders2 weeks ago Summit Therapeutics plc Positive Results From Summit's Phase 2 Codify Trial Presented At 26th Eccmid Conference  ADVFN UK2 weeks ago
[x]  

FDA recommends ban on blood collections from Zika-affected areas

A health technician analyzes blood samples from patients bitten by mosquitoes at the National Institute of Health in Lima, Peru. Reuters Wednesday, Feb 17, 2016 Reuters By Toni Clarke The US Food and Drug Administration recommended on ...
 Asiaone2 months ago

Specialised Therapeutics Asia Pte Ltd Release: Novel Multiple Myeloma Drug Aplidin Shows Positive Results In Pivotal Phase 3 Study

Phase 3 trial of Aplidin®/dexamethasone combination showed statistically significant 35% reduction in risk of disease progression or death compared to dexamethasone alone Drug expected to be available in Australia, SE Asia 2018 Aplidin® is a ...
 BioSpace4 weeks ago Novel Multiple Myeloma Drug Aplidin(R) Shows Positive Results in Pivotal Phase 3 Study  Minyanville4 weeks ago
[x]  

Lattice Biologics and Sunnybrook Research Institute Commence Study to Develop New Cancer Screening Methods

) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce it has entered into an Industry Sponsored Collaboration Agreement with Sunnybrook Research Institute ("SRI") in Toronto, ...
 Quotenet.com1 month ago
[x]  

Iomab-B for the treatment of Refractory and Relapsed Acute Myeloid Leukaemia

Iomab-B is a radio-immunotherapeutic drug developed by Actinium Pharmaceuticals for treatment of refractory and relapsed acute myeloid leukaemia in elderly patients. Actinium Pharmaceuticals has submitted a request for pre-IND (Investigational ...
 Drug Development Technology2 days ago

4/19/16 - Transdermal Delivery Solutions Announces Regulatory Approval of Clinical Trials Commencement of Testagen® Topical Testosterone HypoSpray®

Transdermal Delivery Solutions, a leader in the development of spray-on drug delivery systems, announced today they are entering the pivotal phase of clinical trials PALM BEACH GARDENS, Fla.(BUSINESS WIRE) Transdermal Delivery Solutions ...
 Pharmacy Choice1 week ago Transdermal Delivery Solutions Announces Regulatory Approval of Clinical Trials Commencement of Testagen® Topical Testosterone HypoSpray®  BioMedReports1 week ago TRANSDERMAL DELIVERY SOLUTIONS : Announces Regulatory Approval of Clinical Trials Commencement of Testagen® Topical Testosterone HypoSpray®  4 Traders1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less